Chris Porter
Chris Porter
Director, Monash Institute of Pharmaceutical Sciences, Monash University
Verified email at monash.edu
Title
Cited by
Cited by
Year
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
CJH Porter, NL Trevaskis, WN Charman
Nature reviews Drug discovery 6 (3), 231-248, 2007
14482007
Strategies to address low drug solubility in discovery and development
HD Williams, NL Trevaskis, SA Charman, RM Shanker, WN Charman, ...
Pharmacological reviews 65 (1), 315-499, 2013
9642013
Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies
CW Pouton, CJH Porter
Advanced drug delivery reviews 60 (6), 625-637, 2008
7502008
Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH
WN Charman, CJH Porter, S Mithani, JB Dressman
Journal of pharmaceutical sciences 86 (3), 269-282, 1997
6551997
Enhancing intestinal drug solubilisation using lipid-based delivery systems
CJH Porter, CW Pouton, JF Cuine, WN Charman
Advanced drug delivery reviews 60 (6), 673-691, 2008
6412008
Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine
SM Khoo, AJ Humberstone, CJH Porter, GA Edwards, WN Charman
International journal of pharmaceutics 167 (1-2), 155-164, 1998
4671998
In vitro assessment of oral lipid based formulations
CJH Porter, WN Charman
Advanced drug delivery reviews 50, S127-S147, 2001
4192001
Intestinal lymphatic drug transport: an update
CJH Porter, WN Charman
Advanced drug delivery reviews 50 (1-2), 61-80, 2001
3262001
Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update
NL Trevaskis, WN Charman, CJH Porter
Advanced drug delivery reviews 60 (6), 702-716, 2008
3222008
Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating
SM Moghimi, CJH Porter, IS Muir, L Illum, SS Davis
Biochemical and biophysical research communications 177 (2), 861-866, 1991
3121991
Evaluation of the in‐vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products
L Sek, CJH Porter, AM Kaukonen, WN Charman
Journal of pharmacy and pharmacology 54 (1), 29-41, 2002
2752002
Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility
DB Warren, H Benameur, CJH Porter, CW Pouton
Journal of drug targeting 18 (10), 704-731, 2010
2652010
Effect of short‐, medium‐, and long‐chain fatty acid‐based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of …
SM Caliph, WN Charman, CJH Porter
Journal of pharmaceutical sciences 89 (8), 1073-1084, 2000
2562000
Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation
CJH Porter, AM Kaukonen, BJ Boyd, GA Edwards, WN Charman
Pharmaceutical research 21 (8), 1405-1412, 2004
2432004
Lymphatic transport of proteins after subcutaneous administration
CJH Porter, SA Charman
Journal of pharmaceutical sciences 89 (3), 297-310, 2000
2312000
From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity
NL Trevaskis, LM Kaminskas, CJH Porter
Nature Reviews Drug Discovery 14 (11), 781-803, 2015
2212015
The polyoxyethylene/polyoxypropylene block co‐polymer Poloxamer‐407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow
CJH Porter, SM Moghimi, L Illum, SS Davis
FEBS letters 305 (1), 62-66, 1992
2041992
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine
CJH Porter, AM Kaukonen, A Taillardat-Bertschinger, BJ Boyd, ...
Journal of pharmaceutical sciences 93 (5), 1110-1121, 2004
2002004
Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations
AM Kaukonen, BJ Boyd, CJH Porter, WN Charman
Pharmaceutical research 21 (2), 245-253, 2004
1932004
An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E da-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and …
BM Johnson, WN Charman, CJH Porter
AAPS pharmsci 4 (4), 193-205, 2002
1902002
The system can't perform the operation now. Try again later.
Articles 1–20